---
title: "Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293231242.md"
description: "REGENXBIO announced positive long-term clinical data for its gene therapy sura-vec in wet AMD and diabetic retinopathy, showing sustained visual benefits. Concurrently, the company raised $100 million via a public equity offering of approximately 10 million shares priced at $9.00 each. Shares rose 5.16% following the announcements."
datetime: "2026-07-20T14:45:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293231242.md)
  - [en](https://longbridge.com/en/news/293231242.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293231242.md)
generator: "portal-rs"
---

# Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments

**REGENXBIO Inc**. (NASDAQ:RGNX) on Saturday shared long-term clinical trial findings for its experimental gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) targeting wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).

## Long-Term Efficacy In Wet AMD Treatment

Data presented at the American Society of Retina Specialists Annual Meeting demonstrated that subretinal delivery of sura-vec maintained or enhanced visual acuity over five years in wet AMD patients within Cohorts 3 and 4 of its Phase 1/2a trial.

 **Read Also: Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy** 

Participants experienced significant reductions in anti-VEGF treatment demands without new safety issues or intraocular inflammation among study completers.

In an external comparative study, sura-vec recipients preserved vision, achieved superior visual acuity outcomes, experienced less fluctuation in central retinal thickness, and required far fewer injections after one year compared to real-world anti-VEGF control groups.

Pivotal phase ATMOSPHERE and ASCENT trials, which compare sura-vec against ranibizumab and aflibercept across more than 1,200 subjects, remain on track to release topline results alongside **AbbVie Inc.** (NYSE:ABBV) in late 2026.

## Durable Results In Diabetic Retinopathy

For diabetic retinopathy, extended results from the Phase 2 ALTITUDE trial showed that a single in-office suprachoroidal administration of sura-vec sustained positive safety and performance through 2.5 years.

Among participants receiving Dose Level 3 alongside brief topical steroid regimens, 55% attained a two-step or greater improvement on the Diabetic Retinopathy Severity Scale without needing extra therapy.

Furthermore, 70% of these patients remained free from vision-threatening complications. As of May 25, 2026, no cases of intraocular inflammation were reported in this group.

## Raises $100 Million Via Equity

The company on Friday priced a public stock offering comprising approximately 10 million shares at $9.00 each and 1.11 million pre-funded warrants at $8.9999 apiece, with gross proceeds of around $100 million.

**RGNX Price Action:** Regenxbio shares were up 5.16% at $10.40 at the time of publication on Monday, according to Benzinga Pro data.

 **Read Also: Investors Pour Record $46 Billion Into Semiconductor ETFs. What the Technicals Say Next** 

*Image via Shutterstock/ New Africa*

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial](https://longbridge.com/en/news/298029915.md)
- [Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting](https://longbridge.com/en/news/293104812.md)
- [BLTE: Tinlarebant slowed Stargardt lesion growth and is on track for U.S. launch in March 2027](https://longbridge.com/en/news/297809717.md)
- [Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentation](https://longbridge.com/en/news/297550820.md)
- [FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing | FBLG Stock News](https://longbridge.com/en/news/297917648.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**